Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review

FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.